XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 43.71

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.07 (+0.05%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.12%)

USD 2.70B
FXH First Trust Health Care AlphaD..

-0.53 (-0.50%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

-0.83 (-0.98%)

USD 0.18B
IDNA iShares Genomics Immunology an..

-0.47 (-2.12%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.67 (-2.16%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.12 (+0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.32 (-1.12%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-1.27 (-2.07%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-2.73%)

USD 6.67M

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 10.03 % 0.00 %

-0.23 (-0.85%)

USD 0.11B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.67% 52% F 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.67% 52% F 64% D
Trailing 12 Months  
Capital Gain 2.82% 71% C- 53% F
Dividend Return 1.19% 88% B+ 23% F
Total Return 4.01% 76% C+ 43% F
Trailing 5 Years  
Capital Gain 32.62% 29% F 37% F
Dividend Return 7.79% 68% D+ 14% F
Total Return 40.41% 33% F 29% F
Average Annual (5 Year Horizon)  
Capital Gain -2.27% 19% F 22% F
Dividend Return -1.48% 29% F 15% F
Total Return 0.78% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 15.43% 67% D+ 65% D
Risk Adjusted Return -9.62% 19% F 15% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.